4 Reasons Pfizer Is Now the Ultimate COVID-19 Growth Stock
Unless you've been living under several rocks, it won't come as a surprise to hear that Pfizer (NYSE: PFE) is one of the leaders in the COVID-19 medicine market. Between its wildly successful vaccine and its dutiful development of soon-to-be-released antiviral therapies, the company has risen to meet the moment of the pandemic like few others.
Even if a pharma juggernaut might not sound like a prototypical growth stock to you, by all indications Pfizer is going to keep deepening its lead, potentially delivering market-crushing returns to its investors. Let's take a look at four reasons it's positioned to be the best COVID growth stock on the market for the next few years.
Image source: Getty Images.
Source Fool.com